Approaches for treating neuropsychiatric symptoms in Parkinson's disease: a narrative review

被引:0
作者
Rodriguez-Antiguedad, Jon [1 ,2 ,3 ,4 ]
Olmedo-Saura, Gonzalo [1 ,2 ,3 ,4 ]
Pagonabarraga, Javier [1 ,2 ,3 ,4 ]
Martinez-Horta, Saul [1 ,2 ,3 ,4 ]
Kulisevsky, Jaime [1 ,2 ,3 ,4 ]
机构
[1] Hosp Santa Creu i St Pau, Neurol Dept, Movement Disorders Unit, Mas Casanovas 90, Barcelona 08041, Spain
[2] Univ Autonoma Barcelona UAB, Med Dept, Barcelona, Spain
[3] Inst Invest Biomed St Pau IIB St Pau, Barcelona, Spain
[4] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain
关键词
neuropsychiatric symptoms; non-motor symptoms; Parkinson's disease; treatment; MILD COGNITIVE IMPAIRMENT; IMPULSE CONTROL DISORDERS; QUALITY-OF-LIFE; CLINICAL DIAGNOSTIC-CRITERIA; DEEP BRAIN-STIMULATION; CORTICAL LEWY BODIES; NONMOTOR SYMPTOMS; DOUBLE-BLIND; SUBTHALAMIC STIMULATION; DEPRESSIVE SYMPTOMS;
D O I
10.1177/17562864251336903
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Neuropsychiatric symptoms in Parkinson's disease (PD) are highly prevalent and profoundly disabling, often emerging even before the onset of motor symptoms. As the disease progresses, these symptoms usually become increasingly impairing and are now recognized as having the greatest impact on quality of life not only for patients but also for caregivers. In recent years, there have been significant advances in the diagnosis and management of neuropsychiatric symptoms. However, there are still substantial gaps in therapeutic approaches and algorithms, with limited pharmacological and nonpharmacological treatment options currently available. One of the main reasons for this is the complex molecular and neural bases of these symptoms, which involve both dopaminergic and nondopaminergic neurotransmission systems and extend far beyond the nigrostriatal pathway. As a result, the drugs currently recommended for treating neuropsychiatric symptoms in PD are few and supported by limited evidence. In this context, the experience of the treating neurologist remains critical in selecting the most appropriate individualized therapy. The aim of this paper is to review the available therapeutic options and provide an overview of current research efforts, particularly those focusing on pharmacological treatments.
引用
收藏
页数:20
相关论文
共 192 条
[1]   Predictors of nursing home placement in Parkinson's disease: A population-based, prospective study [J].
Aarsland, D ;
Larsen, JP ;
Tandberg, E ;
Laake, K .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2000, 48 (08) :938-942
[2]   A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia [J].
Aarsland, D ;
Ballard, C ;
Larsen, JP ;
McKeith, I .
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2001, 16 (05) :528-536
[3]   Subthalamic stimulation and neuropsychiatric symptoms in Parkinson's disease: results from a long-term follow-up cohort study [J].
Abbes, Marie ;
Lhommee, Eugenie ;
Thobois, Stephane ;
Klinger, Helene ;
Schmitt, Emmanuelle ;
Bichon, Amelie ;
Castrioto, Anna ;
Xie, Jing ;
Fraix, Valerie ;
Kistner, Andrea ;
Pelissier, Pierre ;
Seigneuret, Eric ;
Chabardes, Stephan ;
Mertens, Patrick ;
Broussolle, Emmanuel ;
Moro, Elena ;
Krack, Paul .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 (08) :836-843
[4]   Cognitive performance of GBA mutation carriers with early-onset PD The CORE-PD study [J].
Alcalay, R. N. ;
Caccappolo, E. ;
Mejia-Santana, H. ;
Tang, M. -X. ;
Rosado, L. ;
Reilly, M. Orbe ;
Ruiz, D. ;
Ross, B. ;
Verbitsky, M. ;
Kisselev, S. ;
Louis, E. ;
Comella, C. ;
Colcher, A. ;
Jennings, D. ;
Nance, M. ;
Bressman, S. ;
Scott, W. K. ;
Tanner, C. ;
Mickel, S. ;
Andrews, H. ;
Waters, C. ;
Fahn, S. ;
Cote, L. ;
Frucht, S. ;
Ford, B. ;
Rezak, M. ;
Novak, K. ;
Friedman, J. H. ;
Pfeiffer, R. ;
Marsh, L. ;
Hiner, B. ;
Siderowf, A. ;
Payami, H. ;
Molho, E. ;
Factor, S. ;
Ottman, R. ;
Clark, L. N. ;
Marder, K. .
NEUROLOGY, 2012, 78 (18) :1434-1440
[5]   Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis [J].
Antonini, A. ;
Chaudhuri, K. R. ;
Boroojerdi, B. ;
Asgharnejad, M. ;
Bauer, L. ;
Grieger, F. ;
Weintraub, D. .
EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 (10) :1556-1565
[6]   Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life [J].
Antonini, Angelo ;
Tesei, Silvana ;
Zecchinelli, Anna ;
Barone, Paolo ;
De Gaspari, Danilo ;
Canesi, Margherita ;
Sacilotto, Giorgio ;
Meucci, Nicoletta ;
Mariani, Claudio ;
Pezzoli, Gianni .
MOVEMENT DISORDERS, 2006, 21 (08) :1119-1122
[7]   Agomelatine for Depression in Parkinson Disease Additional Effect on Sleep and Motor Dysfunction [J].
Avila, Asuncion ;
Cardona, Xavier ;
Martin-Baranera, Montserrat ;
Leon, Lucia ;
Caballol, Nuria ;
Millet, Pablo ;
Bello, Juan .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2015, 35 (06) :719-723
[8]   Effect of donepezil for dementia prevention in Parkinson's disease with severe hyposmia (The DASH-PD study): A randomized long-term placebo-controlled trial [J].
Baba, Toru ;
Takeda, Atsushi ;
Murakami, Aya ;
Koga, Tadashi ;
Isomura, Tatsuya ;
Mori, Etsuro .
ECLINICALMEDICINE, 2022, 51
[9]   Donepezil for mild cognitive impairment in Parkinson's disease [J].
Baik, Kyoungwon ;
Kim, Seon Myeong ;
Jung, Jin Ho ;
Lee, Yang Hyun ;
Chung, Seok Jong ;
Yoo, Han Soo ;
Ye, Byoung Seok ;
Lee, Phil Hyu ;
Sohn, Young H. ;
Kang, Seung Wan ;
Kang, Suk Yun .
SCIENTIFIC REPORTS, 2021, 11 (01)
[10]   Mild Cognitive Impairment and Parkinson's Disease - Something to Remember [J].
Barker, Roger A. ;
Williams-Gray, Caroline H. .
JOURNAL OF PARKINSONS DISEASE, 2014, 4 (04) :651-656